Targeting radiation-induced G 2 checkpoint activation with the wee-1 inhibitor MK-1775 in glioblastoma cell lines

Molecular Cancer Therapeutics

Volumn 10, Issue 12, 2011, Pages 2405-2414

  Sarcar, Bhaswati ^a   Kahali, Soumen ^a   Prabhu, Antony H ^a   Shumway, Stuart D ^b   Xu, Yang ^b   Demuth, Tim ^b   Chinnaiyan, Prakash ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 1; HISTONE H2AX; MK 1775; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTE; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION;

ANIMALS; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; G2 PHASE CELL CYCLE CHECKPOINTS; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83355174034     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0469     Document Type: Article

References (21)

1. Milano MT, Okunieff P, Donatello RS,Mohile NA, Sul J, Walter KA, et al. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 2010;78: 1147-55.
2. Rowley R, Hudson J, Young PG. The wee1 protein kinase is required for radiation-induced mitotic delay. Nature 1992;356:353-5.
3. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-9.
4. Rhind N, Russell P. Roles of the mitotic inhibitors Wee1 and Mik1 in the G(2) DNA damage and replication checkpoints. Mol Cell Biol 2001;21: 1499-508. (Pubitemid 32156370)
5. Xu B, Kim ST, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002; 22:1049-59. (Pubitemid 34094842)
6. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters JW, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011; 17:2799-806.
7. Lundgren K, Walworth N, Booher R, Dembski M, Kirschner M, Beach D. mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 1991;64:1111-22. (Pubitemid 121001198)
8. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009;8:2992-3000.
9. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008;455:1129-33.
10. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
11. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK- 1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-22.
12. Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2011;18:244-57.
13. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumorspecific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009;4:568-80.
14. Kahali S, Sarcar B, Fang B, Williams ES, Koomen JM, Tofilon PJ, et al. Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia 2010;12:80-6.
15. Dirks PB. Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol 2008;26:2916-24.
16. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401. (Pubitemid 39551674)
17. Bao S,WuQ, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
18. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23:2825-37. (Pubitemid 38638845)
19. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61. (Pubitemid 351348146)
20. Li J, Wang Y, Sun Y, Lawrence TS. Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat Res 2002;157:322-30. (Pubitemid 34263846)
21. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001;61:8211-7. (Pubitemid 33091614)